Statins and the Risk of Cancer After Heart Transplantation | Zendy

Georg Fröhlich | Zendy; Kaspar Rufibach | Zendy; Frank Enseleit | Zendy; Mathias Wolfrum | Zendy; Michelle von Babo | Zendy; Michelle Frank | Zendy; Reto Berli | Zendy; Matthias Hermann | Zendy; Johannes Holzmeister | Zendy; Markus J. Wilhelm | Zendy; Volkmar Falk | Zendy; Georg Noll | Zendy; Thomas F. Lüscher | Zendy; Frank Ruschitzka | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Statins and the Risk of Cancer After Heart Transplantation

Author(s) -

Georg Fröhlich,

Kaspar Rufibach,

Frank Enseleit,

Mathias Wolfrum,

Michelle von Babo,

Michelle Frank,

Reto Berli,

Matthias Hermann,

Johannes Holzmeister,

Markus J. Wilhelm,

Volkmar Falk,

Georg Noll,

Thomas F. Lüscher,

Frank Ruschitzka

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.081059

Subject(s) - medicine , hazard ratio , heart transplantation , transplantation , statin , cumulative incidence , malignancy , cancer , proportional hazards model , confidence interval , surgery , oncology

Although newer immunosuppressive agents, such as mTOR (mammalian target of rapamycin) inhibitors, have lowered the occurrence of malignancies after transplantation, cancer is still a leading cause of death late after heart transplantation. Statins may have an impact on clinical outcomes beyond their lipid-lowering effects. The aim of the present study was to delineate whether statin therapy has an impact on cancer risk and total mortality after heart transplantation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research